In a tumour-bearing mouse model, an SREBP1 inhibitor led to a large lack of free fatty acids and resulted in an increase in CD8+ T cells and a decrease in M2 TAMs under combined treatment with anti-PD-1 therapy, enhanced antitumour immunity and inhibited tumour growth [135]. This evidence concerns the gene SREBF1 and neoplasm.